Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39

J. Tuzil, BF. Pilnackova, T. Watt, J. Jiskra, M. Koudelkova, E. Novotna, K. Tuzilova, T. Dolezal, J. Bartakova

. 2023 ; 26 (7) : 1085-1097. [pub] 20230305

Language English Country United States

Document type Clinical Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23017024

OBJECTIVES: To describe how subclinical hypothyroidism (SubHypo) influences the quality of life (QoL) during pregnancy. METHODS: In primary data collection (NCT04167423), thyroid stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase antibodies, generic quality of life (QoL; 5-level version of EQ-5D [EQ-5D-5L]), and disease-specific QoL (ThyPRO-39) were measured among pregnant women. SubHypo during each trimester was defined according to the 2014 European Thyroid Association guidelines (TSH > 2.5, 3.0, and 3.5 IU/L, respectively; with normal FT4). Path analysis described relationships and tested mediation. Linear ordinary least squares, beta, tobit, and two-part regressions were used to map ThyPRO-39 and EQ-5D-5L. Alternative SubHypo definition was tested in sensitivity analysis. RESULTS: A total of 253 women at 14 sites (31 ± 5 years old, 15 ± 6 weeks pregnant) completed the questionnaires. Sixty-one (26%) had SubHypo and differed from 174 (74%) euthyroid women in smoking history (61% vs 41%), primiparity (62% vs 43%) and TSH level (4.1 ± 1.4 vs 1.5 ± 0.7 mIU/L, P < .001). EQ-5D-5L utility in SubHypo (0.89 ± 0.12) was lower than that in euthyroid (0.92 ± 0.11; P = .028) even after adjustment (difference -0.04, P = .033), whereas ocular (P = .001, ThyPRO-39), cognitive symptoms (P = .043), anxiety (P < .0001), and the composite score were higher. The impact of SubHypo on utility was mediated by anxiety. Results were confirmed by sensitivity analysis. Final mapping equation (ordinary least squares) includes goiter symptoms, anxiety, upset stomach, composite score (ThyPRO-39), FT4 levels, and week of pregnancy (determination coefficient 0.36). CONCLUSION: This is the first QoL mapping of SubHypo during pregnancy and the first evidence that SubHypo is associated with a negative impact on QoL. The effect is mediated by anxiety. EQ-5D-5L utilities can be generated based on ThyPRO-39 scores collected in pregnant euthyroid and patients with SubHypo.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017024
003      
CZ-PrNML
005      
20231026105331.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jval.2023.02.015 $2 doi
035    __
$a (PubMed)36878311
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tuzil, Jan $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic; First Medical Faculty, Charles University, Prague, Czech Republic. Electronic address: tuzil.jenik@gmail.com
245    14
$a The Impact of Subclinical Hypothyroidism on the Quality of Life During Pregnancy: Mapping 5-Level Version of EQ-5D and ThyPRO-39 / $c J. Tuzil, BF. Pilnackova, T. Watt, J. Jiskra, M. Koudelkova, E. Novotna, K. Tuzilova, T. Dolezal, J. Bartakova
520    9_
$a OBJECTIVES: To describe how subclinical hypothyroidism (SubHypo) influences the quality of life (QoL) during pregnancy. METHODS: In primary data collection (NCT04167423), thyroid stimulating hormone (TSH), free thyroxine (FT4), thyroid peroxidase antibodies, generic quality of life (QoL; 5-level version of EQ-5D [EQ-5D-5L]), and disease-specific QoL (ThyPRO-39) were measured among pregnant women. SubHypo during each trimester was defined according to the 2014 European Thyroid Association guidelines (TSH > 2.5, 3.0, and 3.5 IU/L, respectively; with normal FT4). Path analysis described relationships and tested mediation. Linear ordinary least squares, beta, tobit, and two-part regressions were used to map ThyPRO-39 and EQ-5D-5L. Alternative SubHypo definition was tested in sensitivity analysis. RESULTS: A total of 253 women at 14 sites (31 ± 5 years old, 15 ± 6 weeks pregnant) completed the questionnaires. Sixty-one (26%) had SubHypo and differed from 174 (74%) euthyroid women in smoking history (61% vs 41%), primiparity (62% vs 43%) and TSH level (4.1 ± 1.4 vs 1.5 ± 0.7 mIU/L, P < .001). EQ-5D-5L utility in SubHypo (0.89 ± 0.12) was lower than that in euthyroid (0.92 ± 0.11; P = .028) even after adjustment (difference -0.04, P = .033), whereas ocular (P = .001, ThyPRO-39), cognitive symptoms (P = .043), anxiety (P < .0001), and the composite score were higher. The impact of SubHypo on utility was mediated by anxiety. Results were confirmed by sensitivity analysis. Final mapping equation (ordinary least squares) includes goiter symptoms, anxiety, upset stomach, composite score (ThyPRO-39), FT4 levels, and week of pregnancy (determination coefficient 0.36). CONCLUSION: This is the first QoL mapping of SubHypo during pregnancy and the first evidence that SubHypo is associated with a negative impact on QoL. The effect is mediated by anxiety. EQ-5D-5L utilities can be generated based on ThyPRO-39 scores collected in pregnant euthyroid and patients with SubHypo.
650    _2
$a dospělí $7 D000328
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a těhotenství $7 D011247
650    _2
$a úzkost $7 D001007
650    12
$a hypotyreóza $7 D007037
650    12
$a kvalita života $x psychologie $7 D011788
650    _2
$a průzkumy a dotazníky $7 D011795
650    _2
$a thyreotropin $7 D013972
655    _2
$a klinická studie $7 D000068397
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pilnackova, Barbora Filkova $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic
700    1_
$a Watt, Torquil $u Department of Internal Medicine, Endocrinology, Herlev Gentofte Hospital, Copenhagen, Denmark
700    1_
$a Jiskra, Jan $u Third Department of Internal Medicine, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Koudelkova, Marcela $u Institute of Health Information and Statistics of the Czech Republic, National Screening Centre, Praha, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Novotna, Eva $u Outpatient gynecology Femcare s.r.o., Odolena Voda, Czech Republic
700    1_
$a Tuzilova, Klara $u GYNO SANET s.r.o., Prague, Czech Republic
700    1_
$a Dolezal, Tomas $u Institute of Health Economics and Technology Assessment, Prague, Czech Republic; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Bartakova, Jana $u Department of Public Health, Institute of Nursing Science, Faculty of Medicine, University of Basel, Basel, Switzerland; Health Economics Facility, Department of Public Health, University of Basel, Basel, Switzerland
773    0_
$w MED00007383 $t Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research $x 1524-4733 $g Roč. 26, č. 7 (2023), s. 1085-1097
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36878311 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105325 $b ABA008
999    __
$a ok $b bmc $g 2000509 $s 1203386
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 26 $c 7 $d 1085-1097 $e 20230305 $i 1524-4733 $m Value in health $n Value Health $x MED00007383
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Archiving options